However, the prevalence of functional PIK3CA mutations was similar between the two groups (HER2+/ER+=29.5%, HER2+/ER−=30.1%), although there were significantly fewer PIK3CA mutations in HER2+/ER+ tumours than in HER2−/ER+ tumours (46.5%). Here, ESR1 is linked to neoplasm.